A Survey Study to See if Patients Diagnosed With Parkinson's Disease Have Higher Incidence of Melanoma - Tabular View

Tracking Information

First Received Date ^ICMJE

September 13, 2005

Last Updated Date

December 11, 2007

Start Date ^ICMJE

January 2003

Primary Completion Date

Current Primary Outcome Measures ^ICMJE

Original Primary Outcome Measures ^ICMJE

Change History

Complete list of historical versions of study NCT00203008 on ClinicalTrials.gov Archive Site

Current Secondary Outcome Measures ^ICMJE

Original Secondary Outcome Measures ^ICMJE

Descriptive Information

Brief Title ^ICMJE

A Survey Study to See if Patients Diagnosed With Parkinson's Disease Have Higher Incidence of Melanoma

Official Title ^ICMJE

A Survey to Assess the Incidence and Characteristics of Melanoma in Parkinson's Disease Patients

Brief Summary

Patients with Parkinson's disease will be seen by a dermatologist who will biopsy any suspicious skin lesions.

Detailed Description

Study Phase

Study Type ^ICMJE

Observational

Study Design ^ICMJE

Other

Condition ^ICMJE

Parkinsons Disease
Malignant Melanoma

Intervention ^ICMJE

Study Arms / Comparison Groups

Publications *

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status ^ICMJE

Completed

Enrollment ^ICMJE

2106

Completion Date

September 2003

Primary Completion Date

Eligibility Criteria ^ICMJE

Inclusion Criteria:

Confirmed diagnosis Parkinson's disease Patient able and willing to give informed consent Patient must not be taking any investigational drug at the time of enrollment

Exclusion Criteria:

Gender

Both

Ages

Accepts Healthy Volunteers

Contacts ^ICMJE

Contact information is only displayed when the study is recruiting subjects

Location Countries ^ICMJE

United States, Canada

Administrative Information

NCT ID ^ICMJE

NCT00203008

Responsible Party

J. Michael Nicholas, PhD, Sr. Director, Teva Neuroscience

Study ID Numbers ^ICMJE

EP002

Study Sponsor ^ICMJE

Teva Pharmaceutical Industries

Collaborators ^ICMJE

Investigators ^ICMJE

Study Director:

Bruce Schwartz, Ph.D.

Teva Neuroscience, Inc.

Information Provided By

Teva Pharmaceutical Industries

Verification Date

December 2007

^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP